Gene expression profiling of HepG2 cells after treatment of PD-0332991 and CDK4-6 Knockdown

The aim of this study is to estimate gene expression variations involved in glucose meatbolism in HepG2 cell line after cell cycle(G1 to S phase) inhibition by using drug(PD-0332991) or CDK4-6-knock down. We hypothesized that transition of glycolytic gene expression might indicates the effect of PD-0332991 drug treatment in Hepatocellular carcinoma cells. Examination of 2 different treatment conditions in 1cell line, using Illumina NextSeq500. Sample conditions: Control(DMSO) and PD-0332991 treated-HepG2, SC and CDK4-6-Knock down-HepG2 cells.